Also known as: Xarelto API; Factor Xa Inhibitor
Rivaroxaban is a direct oral anticoagulant (DOAC) and active pharmaceutical ingredient that selectively inhibits Factor Xa. Mediocon Inc supplies high-purity Rivaroxaban API conforming to IP / BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.
Rivaroxaban prevents thrombus formation by directly inhibiting coagulation Factor Xa, reducing thrombin generation. It is indicated for stroke prevention in atrial fibrillation, treatment of DVT and PE, and post-surgical thromboprophylaxis.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Rivaroxaban (CAS 366789-02-8) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Rivaroxaban is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance